News & Updates
Filter by Specialty:
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
28 Oct 2022
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
25 Oct 2022
Baseline HRQOL predicts survival in after radical prostatectomy
Baseline health-related quality of life (HRQOL) among patients with localized high-risk prostate cancer prior to radical prostatectomy is an important and a strong predictor of survival, suggests a study.
Baseline HRQOL predicts survival in after radical prostatectomy
24 Oct 2022
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
In the treatment of patients with ICI-naïve nonsmall cell lung cancer (NSCLC), adding the cytotoxic chemotherapy docetaxel to the immune-checkpoint inhibitor (ICI) nivolumab leads to a significantly longer survival, although at the expense of slightly elevated toxicity, according to the results of a phase II/III trial.
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat
20 Oct 2022
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC
Adjuvant pembrolizumab significantly improves disease-free survival (DFS) vs placebo in patients with completely resected, PD-L1–unselected, stage IB–IIIA non-small-cell lung cancer (NSCLC), a second interim analysis of the triple-blind phase III PEARLS/KEYNOTE-091 trial has shown.
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC
20 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
SLN status delivers vital prognosis in stage IIB/C cutaneous melanoma
The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.
